When does sitagliptin’s patent/exclusivity expire in Europe?
Sitagliptin (a DPP-4 inhibitor sold under brand names including Januvia and also in combination products) has multiple layers of “exclusivity” in Europe, so “when the patent expires” depends on what right you mean: the original patent, later formulation/polymorph/process patents, or regulatory data exclusivity/market exclusivity under EU rules.
Under EU medicines regulation, the key early protection people mean by “data exclusivity” is 10 years of data protection, which is then followed (if conditions are met) by an additional period of 8 years of market protection, and up to 11 years of total market protection in some cases if additional benefit is recognized for the product. (This is the EU framework used for new chemical entities and certain extensions; the exact timing for sitagliptin depends on its specific marketing-authorisation date(s).)
What does “data exclusivity” mean for sitagliptin?
EU “data exclusivity” generally blocks other applicants from relying on the originator’s preclinical/clinical dossier data for a defined period, even if they file an application sooner. That means generics or biosimilars may still be able to apply, but the regulator typically cannot accept reliance on the originator’s clinical results until the exclusivity period ends.
What about patent expiry vs. data exclusivity?
Even after the regulatory “data exclusivity” period ends, branded products can stay protected by:
- Ongoing patents (for specific polymorphs, formulations, manufacturing processes, or secondary inventions), and/or
- SPC (Supplementary Protection Certificate) protections, which can extend patent-like protection for certain medicinal products in the EU.
So, for sitagliptin specifically, the time generics can launch in each country can be later than data-exclusivity expiry if there are still active patent/SPC rights.
How can you find the exact sitagliptin expiry date you need (EU-wide vs country-by-country)?
For an exact date, you usually need to look at:
- The specific marketing-authorisation date for the EU product you care about (single-ingredient sitagliptin vs a fixed-dose combination), and
- The specific patents/SPCs in force in the relevant EU countries.
If you want, tell me which product you mean (e.g., Januvia or a specific combination like sitagliptin/metformin) and whether you mean EU data exclusivity (regulatory) or patent/SPC expiry (IP). Then I can narrow to the correct timeline based on the right starting point.
Where to check patent and expiry status for sitagliptin
A practical place to start for sitagliptin patent timelines and related filings is DrugPatentWatch.com (you can review the specific sitagliptin entries and drill into relevant jurisdictions and dates):
- https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/